Abstract 1393P
Background
Patients with driver-gene mutations in NSCLC can benefit significantly from corresponding targeted therapy, but respond poorly to immunotherapy (such as EGFR, ALK). As a driver-gene of NSCLC, the relationship between the characteristics of MET and many immune indicators in the Chinese population is still unclear. This study aims to elucidate the characteristics of the MET gene and its relationship with immune indicators in the Chinese NSCLC population.
Methods
732 Formalin-Fixed Paraffin-Embedded (FFPE) lung adenocarcinoma samples were collected and detected by Next Generation Sequencing 603-gene panel from July, 2021 to March, 2023 were selected from the study. The biomarkers of immunotherapy (TMB-High [≥10/Mb], and MMR-related genes (MLH1, MSH2, MSH6, PMS2) were also calculated.
Results
Among the 732 subjects included in the previous detection, a total of 32 cases were detected to carry MET-related mutations. The detection rate of MET gene was 4.37%. The median age was 65 (13-97). 15% of patients belonged to exon 14 skipping type (5/32); MET amplification accounted for the least, accounting for only 6% (2/32 ). The top 3 of mutation frequency were Met_L221W (4/32), MET_Q1067K (2/32), and MET_F206S (2/32). The gene partners of Met co-mutation were analyzed, and the top five genes were PPP2R1A, HIST1H3G, CDKN1B, SYK, and ERBB4. In the analysis of the immune indicators of the MET mutant population and wild-type population, the Mann-Whitney U test found that among the TMB indicators, the mean value of the MET group was 8.09 with SD of 7.91, and the mean value of the un-MET group was 5.94 with SD of 4.98. MET was correlated with TMB with statistical difference (P value 0.02).We also paid attention to MET and MMR-related genes. The analysis showed that there was a significant relationship between MET group and wild-type MET group and MMR gene (p-value: 0.026).
Conclusions
In the Chinese NSCLC population, there is a correlation between MET expression and TMB, and the MET mutation will increase the TMB value. MET expression was significantly correlated with MMR-related gene mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20